Prevalence of Glaucoma Among US Adults in 2022.

IF 7.8 1区 医学 Q1 OPHTHALMOLOGY JAMA ophthalmology Pub Date : 2024-10-17 DOI:10.1001/jamaophthalmol.2024.3884
Joshua R Ehrlich,Zeb Burke-Conte,John S Wittenborn,Jinan Saaddine,John D Omura,David S Friedman,Abraham D Flaxman,David B Rein
{"title":"Prevalence of Glaucoma Among US Adults in 2022.","authors":"Joshua R Ehrlich,Zeb Burke-Conte,John S Wittenborn,Jinan Saaddine,John D Omura,David S Friedman,Abraham D Flaxman,David B Rein","doi":"10.1001/jamaophthalmol.2024.3884","DOIUrl":null,"url":null,"abstract":"Importance\r\nGlaucoma is the leading cause of irreversible blindness worldwide and, in the US, disproportionately affects people from racial and ethnic minority groups. Glaucoma prevalence has not been estimated for the US in more than a decade, and state- and county-level estimates are not available.\r\n\r\nObjective\r\nTo estimate glaucoma and vision-affecting glaucoma prevalence by demographic factors and US state and county for the Centers for Disease Control and Prevention's Vision and Eye Health Surveillance System (VEHSS).\r\n\r\nData Sources\r\nThis meta-analysis used data from the National Health and Nutrition Examination Survey (2005-2008), Medicare fee-for-service claims (2019), IBM MarketScan commercial insurance claims (2016), population-based studies of eye disease (1985-2003), and 2022 population estimates from the US Census Bureau.\r\n\r\nStudy Selection\r\nPubMed was searched for population-based studies of glaucoma prevalence published between 1991 and 2016.\r\n\r\nData Extraction and Synthesis\r\nBayesian meta-regression methods were used to estimate the prevalence of glaucoma and vision-affecting glaucoma stratified by age, undifferentiated sex/gender (a measure that captures an unclear mix of aspects of sex and or gender), race and ethnicity, and US county and state.\r\n\r\nMain Outcomes and Measures\r\nPrevalence of any type of glaucoma (open or closed angle) among people 18 years or older and vision-affecting glaucoma, defined as glaucoma and a visual field abnormality.\r\n\r\nResults\r\nFor 2022, an estimated 4.22 million people (95% uncertainty interval [UI], 3.46 million to 5.23 million) in the US were living with glaucoma, with a prevalence of 1.62% (UI, 1.33%-2.00%) among people 18 years or older and 2.56% (UI, 2.10%-3.16%) among people 40 years or older. An estimated 1.49 million people (UI, 1.17 million to 1.90 million) were living with vision-affecting glaucoma, with a prevalence of 0.57% (UI, 0.45%-0.73%) among people 18 years or older and 0.91% (UI, 0.71%-1.16%) among people 40 years or older. Prevalence of glaucoma among people 18 years or older ranged from 1.11% (UI, 0.89%-1.40%) in Utah to 1.95% (UI, 1.57%-2.39%) in Mississippi. Black adults had a prevalence of 3.15% (UI, 2.32%-4.09%) compared with 1.42% (UI, 1.10%-1.85%) among White adults; adults in the Hispanic and all other racial and ethnic categories combined had a prevalence of 1.56% (UI, 1.13%-2.06%).\r\n\r\nConclusions and Relevance\r\nThis meta-analysis found that an estimated 2.56% of people 40 years or older have glaucoma, slightly more than estimated by previous studies. Black individuals are disproportionately affected. Prevalence estimates at the state and county level can help guide public health planning.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"232 1","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaophthalmol.2024.3884","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Importance Glaucoma is the leading cause of irreversible blindness worldwide and, in the US, disproportionately affects people from racial and ethnic minority groups. Glaucoma prevalence has not been estimated for the US in more than a decade, and state- and county-level estimates are not available. Objective To estimate glaucoma and vision-affecting glaucoma prevalence by demographic factors and US state and county for the Centers for Disease Control and Prevention's Vision and Eye Health Surveillance System (VEHSS). Data Sources This meta-analysis used data from the National Health and Nutrition Examination Survey (2005-2008), Medicare fee-for-service claims (2019), IBM MarketScan commercial insurance claims (2016), population-based studies of eye disease (1985-2003), and 2022 population estimates from the US Census Bureau. Study Selection PubMed was searched for population-based studies of glaucoma prevalence published between 1991 and 2016. Data Extraction and Synthesis Bayesian meta-regression methods were used to estimate the prevalence of glaucoma and vision-affecting glaucoma stratified by age, undifferentiated sex/gender (a measure that captures an unclear mix of aspects of sex and or gender), race and ethnicity, and US county and state. Main Outcomes and Measures Prevalence of any type of glaucoma (open or closed angle) among people 18 years or older and vision-affecting glaucoma, defined as glaucoma and a visual field abnormality. Results For 2022, an estimated 4.22 million people (95% uncertainty interval [UI], 3.46 million to 5.23 million) in the US were living with glaucoma, with a prevalence of 1.62% (UI, 1.33%-2.00%) among people 18 years or older and 2.56% (UI, 2.10%-3.16%) among people 40 years or older. An estimated 1.49 million people (UI, 1.17 million to 1.90 million) were living with vision-affecting glaucoma, with a prevalence of 0.57% (UI, 0.45%-0.73%) among people 18 years or older and 0.91% (UI, 0.71%-1.16%) among people 40 years or older. Prevalence of glaucoma among people 18 years or older ranged from 1.11% (UI, 0.89%-1.40%) in Utah to 1.95% (UI, 1.57%-2.39%) in Mississippi. Black adults had a prevalence of 3.15% (UI, 2.32%-4.09%) compared with 1.42% (UI, 1.10%-1.85%) among White adults; adults in the Hispanic and all other racial and ethnic categories combined had a prevalence of 1.56% (UI, 1.13%-2.06%). Conclusions and Relevance This meta-analysis found that an estimated 2.56% of people 40 years or older have glaucoma, slightly more than estimated by previous studies. Black individuals are disproportionately affected. Prevalence estimates at the state and county level can help guide public health planning.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2022 年美国成年人青光眼患病率。
重要性青光眼是导致全球不可逆转性失明的主要原因,在美国,青光眼对少数民族群体的影响尤为严重。十多年来,美国一直未对青光眼患病率进行估算,也没有州和县一级的估算数据。目标根据人口统计学因素和美国疾病控制与预防中心的视力与眼健康监测系统(VEHSS)对青光眼和影响视力的青光眼患病率进行估算。数据来源这项荟萃分析使用的数据来自美国国家健康与营养检查调查(2005-2008年)、医疗保险付费服务索赔(2019年)、IBM MarketScan商业保险索赔(2016年)、基于人群的眼病研究(1985-2003年)以及美国人口普查局的2022年人口估计值。研究选择在PubMed上搜索了1991年至2016年间发表的基于人群的青光眼患病率研究。数据提取与综合贝叶斯元回归方法用于估算青光眼和影响视力的青光眼的患病率,并按年龄、未区分的性别(一种捕捉性和或性别的不明确组合的测量方法)、种族和民族以及美国县和州进行分层。主要结果和测量18 岁及以上人群中任何类型青光眼(开角型或闭角型)的患病率以及影响视力的青光眼(定义为青光眼和视野异常)的患病率。22万人(95%不确定区间[UI],346万至523万人)患有青光眼,其中18岁或18岁以上人群的患病率为1.62%(UI,1.33%-2.00%),40岁或40岁以上人群的患病率为2.56%(UI,2.10%-3.16%)。估计有 149 万人(UI,117 万至 190 万)患有影响视力的青光眼,其中 18 岁及以上人群的患病率为 0.57%(UI,0.45%-0.73%),40 岁及以上人群的患病率为 0.91%(UI,0.71%-1.16%)。18 岁或以上人群中青光眼的患病率从犹他州的 1.11%(UI,0.89%-1.40%)到密西西比州的 1.95%(UI,1.57%-2.39%)不等。黑人成年人的患病率为 3.15%(UI,2.32%-4.09%),而白人成年人的患病率为 1.42%(UI,1.10%-1.85%);西班牙裔成年人和所有其他种族和族裔成年人的患病率总和为 1.56%(UI,1.13%-2.06%)。黑人受到的影响更大。州和县一级的患病率估计值有助于指导公共卫生规划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
JAMA ophthalmology
JAMA ophthalmology OPHTHALMOLOGY-
CiteScore
13.20
自引率
3.70%
发文量
340
期刊介绍: JAMA Ophthalmology, with a rich history of continuous publication since 1869, stands as a distinguished international, peer-reviewed journal dedicated to ophthalmology and visual science. In 2019, the journal proudly commemorated 150 years of uninterrupted service to the field. As a member of the esteemed JAMA Network, a consortium renowned for its peer-reviewed general medical and specialty publications, JAMA Ophthalmology upholds the highest standards of excellence in disseminating cutting-edge research and insights. Join us in celebrating our legacy and advancing the frontiers of ophthalmology and visual science.
期刊最新文献
Long-Term Blood Pressure Variability and Visual Field Progression in Glaucoma Viral Meningoencephalitis and Bilateral Blurry Vision Negative Treponemal Serologies in Syphilitic Panuveitis Implications of Diagnostic Error in Ocular Surface Disease: The Role of Anchoring and Ambiguous Diagnostic Terminology. Performance of Polygenic Risk Scores for Primary Open-Angle Glaucoma in Populations of African Descent.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1